Latest on Pharmaceutical Industry


EU medicines agency recommends approval of Novartis leukaemia drug Rydapt

A European Medicines Agency (EMA) panel recommended on Friday approval of a new Novartis drug to be used against a tough-to-cure form of blood cancer as the Swiss drugmaker makes headway on refreshing its oncology portfo..Read More...

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma. In May, Bavencio was approved by the ..Read More...



6th European Trial Master File Summit

London Marriott Hotel Regents Park,
United Kingdom,
ExL Events

Press Releases

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

JanssenCilag International NV announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has issued a Positive Opinion recommending marketing authorisation for SYMTUZA dar.. Read More...

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

Churchill Pharmaceuticals LLC a privately held company devoted to expanding treatment options with oral oncology agents announces that the New Drug Application NDA for YONSA abiraterone acetate ultramicrosize tablets has.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics